Clinical factors predicting nemolizumab response in atopic dermatitis [PDF]
Journal of Allergy and Clinical Immunology: GlobalClinical predictors of response to nemolizumab, an anti-IL-31 receptor A antibody, were evaluated in patients with atopic dermatitis (AD). In a retrospective study of 14 Japanese patients, longer disease duration was significantly associated with poor ...
Yumi Masuo, MD +4 more
doaj +4 more sources
Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials [PDF]
Anais Brasileiros de DermatologiaBackground Prurigo nodularis (PN) is a chronic, debilitating inflammatory skin disorder characterized by persistent itching, firm pruritic nodular lesions, and evidence of frequent scratching, like excoriation, and lichenification.
Ana Carolina Putini Vieira +4 more
doaj +2 more sources
Comparative safety profiles of dupilumab and nemolizumab in prurigo nodularis: an indirect META-analysis to inform clinical decision-making [PDF]
Frontiers in MedicineBackgroundPrurigo nodularis (PN), a chronic inflammatory skin disease with significant disease burden, lacks effective therapies. Dupilumab (IL-4Rα inhibitor) and nemolizumab (IL-31 receptor antagonist) show efficacy in trials but have heterogeneous ...
Wenzhe Feng +3 more
doaj +2 more sources
Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach [PDF]
Dermatology and TherapyIntroduction Nemolizumab is a humanized monoclonal antibody targeting interleukin-31 receptor A. It has shown efficacy in treating patients with prurigo nodularis (PN).
Tomoki Takechi +3 more
doaj +2 more sources
The Efficacy and Safety of Nemolizumab in Patients with Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [PDF]
Dermatology Practical & ConceptualHicham Titou
doaj +5 more sources
Breakthrough in Pediatric Atopic Dermatitis Therapy: The Role of Monoclonal Antibodies as a New Hope for Targeted Treatment in Children [PDF]
Quality in SportAims: Atopic dermatitis (AD) is a prevalent skin condition affecting children of all ages and ethnicities. The aim of this review paper is to explore emerging treatments for atopic dermatitis, with a focus on the latest advancements in monoclonal ...
Julia Sosin +6 more
doaj +3 more sources
Nemolizumab for the treatment of atopic dermatitis
Journal of Dermatological TreatmentPurpose Atopic dermatitis (AD) is a common, heterogeneous inflammatory skin disease characterized by chronic or relapsing eczematous lesions and intense pruritus, leading to reduced quality of life and increased mental health burden.
Erica Rodrigues +4 more
doaj +2 more sources
Cutaneous Adverse Events Following Nemolizumab Administration: A Review. [PDF]
J Clin MedAtopic dermatitis (AD) is a chronic inflammatory skin disease characterized by epidermal barrier dysfunction and immune dysregulation, with interleukin (IL)-4, IL-13, and IL-31 recognized as key mediators. Prurigo nodularis (PN) is another chronic inflammatory disorder driven by T helper type 2-mediated inflammation and neural dysregulation, leading to
Mima Y, Yamamoto M, Iozumi K.
europepmc +3 more sources
Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases [PDF]
Frontiers in Immunology, 2019 Many autoimmune skin diseases, such as bullous pemphigoid (BP), psoriasis and certain types of chronic urticaria, are associated with intensive pruritus.
Bernhard F. Gibbs +2 more
doaj +3 more sources
Novel therapeutic use of nemolizumab for refractory chronic scalp dysesthesia [PDF]
JAAD Case ReportsLauren Kuan, BA +2 more
doaj +2 more sources